Laboratorio de análisis Echevarne



Preeclampsia is a disease associated with hypertension during pregnancy. It can lead to serious complications, both in the mother and in the foetus, and is only resolved with the birth.

Which patients is it most useful for?

Pregnant women with a risk factor that could trigger preeclampsia:

It can appear early (<34 weeks of gestation) due to abnormal placental implantation or late (> 34 weeks), presenting fewer risks in the maternal-foetal prognosis.


Improves the prediction of preeclampsia
  • Improves risk stratification and management of preeclampsia.
  • In the first half of pregnancy: identification of pregnant women who can benefit from prophylactic measures (11-13 weeks) or from intensive follow-up (20-24 weeks).
  • Identifies clinical situations such as HELLP syndrome (haemolysis, elevated liver enzymes and low platelet count) that do not always present hypertension and proteinuria.
Early diagnosis
  • Low levels of PIGF and high levels of sFlt1 can be measured up to five weeks before the onset of clinical symptoms.
  • The sFlt1/PIGF ratio has a sensitivity and specificity greater than 95% for the diagnosis of early preeclampsia, once established by clinical criteria.
  • A high ratio or a rapid increase in the proportion warns of the risk of an imminent delivery.
Differential diagnosis
  • Performs the differential diagnosis between preeclampsia and the exacerbation of other diseases that can mimic the same clinical picture.
  • Identification of favourable cases for conservative treatment.
  • Selection of candidates for future preventive and curative treatments.

What does it analyse?

At Laboratorio Echevarne we present a test capable of the early diagnosis of preeclampsia through a blood test. This test uses levels of two angiogenic markers, sFlt1 and PIGF, which makes it possible to identify women who will develop preeclampsia, as their PIGF levels are lower than in normal pregnancies and those of sFlt1 are higher and increase earlier.

PIGF: Pro-angiogenic factor that stimulates the formation of blood vessels in the placenta
sFlt1: Anti-angiogenic factor. Vascular endothelial growth factor receptor
The sFlt-1/PlGF ratio makes it possible to diagnose pre-eclampsia before clinical symptoms arrive

Otros Análisis Destacados

Consult your results